Prestigious business award presented by Lord Lieutenant of Oxfordshire
Concateno, Europe’s leading drug and alcohol test provider, has been presented with the prestigious Queen’s Award for Enterprise in recognition of its outstanding innovation and commercial performance.
The event, which took place at Concateno’s head office in Abingdon on July 7, was attended by more than 100 people, including Concateno staff, clients and other guests. It included a tour of Concateno’s Abingdon laboratories and an exclusive preview of Concateno’s new and innovative products, due to be launched later this year. Following speeches from Concateno’s new chairman and chief executive, Peter Welch, the award was presented by the Lord Lieutenant of Oxfordshire, and representative for The Queen, Tim Stevenson OBE.
Welch said: “This is a momentous occasion for Concateno and we are extremely proud of all our staff that have worked so to gain this recognition. Winning the Queen’s Award for Innovation is a huge achievement, especially as Concateno contested several hundred other organisations to win.”
Concateno was selected for the Queen’s Award as one of 38 organisations out of 414 entries. A major contributing factor towards Concateno’s award was its innovative oral fluid mobile drugs of abuse detection system, the Cozart® DDS®, developed using world-leading technology. The DDS is an innovative breakthrough in drug detection technology, which has helped improve the efficiency of police officers, healthcare professionals and others around the world by significantly speeding up sample analysis at point of care.
The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a business and is the UK’s top award for business performance. Awards are made by Her Majesty The Queen on the advice of the Prime Minister and his advisory committee, comprised of leading industry leaders and government representatives, for special contributions towards innovation and commercial success.
Ends
For more information regarding Concateno, please contact:
Carrie Lowe or Matt Trace
Telephone: +44 (0)1962 893 893
Mobile: +44 (0)7554 014 188 / (0)7828 663 988
Email: [email protected] / [email protected]
Concateno – global drug testing services
Informed testing for informed decisions, when it matters most
Concateno (www.concateno.com) brings together Europe’s strongest and most experienced drug and alcohol testing organisations and over 60 years of collected expertise. It offers an unparalleled breadth of advisory services and testing capabilities – spanning laboratory, point of care tests and all sample types for any biological specimen, including urine, oral fluids, hair and sweat.
Concateno’s 400 employees perform and deliver more than 10 million tests annually, supported by a global network of 600 sample collection officers, trained in-house in chain-of-custody procedures. Together, they conduct testing for approximately 8,500 clients in 130 countries around the world across all industries, healthcare and government bodies.
Concateno’s dedicated divisions specialise in: Child Protection, Clinical Diagnostics, Criminal Justice, Employee Services, Healthcare and Maritime.
Quality is assured by the highest levels of accreditation, supported by expert and responsive customer service. Concateno’s three UK laboratories are audited and accredited by the United Kingdom Accreditation Service (UKAS) to the international standard ISO/IEC 17025 for the testing for substance misuse in hair, oral fluids and urine, respectively. Laboratory products and point of care test products are manufactured within ISO 9001:2008 and ISO 13485:2003 certified facilities. The company is also subject to a range of external quality assurance programmes, including UKNEQAS, IIP and CAP (US scheme).
In August 2009, Concateno became a subsidiary of Inverness Medical Innovations, Inc. (NYSE: IMA).
About Inverness Medical
By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations (www.invernessmedical.com) enables individuals to take charge of improving their health and quality of life at home. Inverness’ global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women’s health. Inverness is headquartered in Waltham, Massachusetts.
